Seaport Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SPTX Nasdaq 2830 www.seaporttx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Seaport Therapeutics, Inc.

Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value? - Oct 25th, 2026 4:08 pm
Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage - Oct 25th, 2026 9:17 am
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress - Oct 9th, 2026 11:00 am
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress - Oct 9th, 2026 5:00 am
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance - Oct 7th, 2026 11:00 am
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance - Oct 7th, 2026 5:00 am
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ... - Sep 22nd, 2026 1:00 pm
PureTech Health H1 Earnings Call Highlights - Sep 22nd, 2026 4:03 am
Seaport Therapeutics to Participate in September Investor Conferences - Sep 14th, 2026 5:00 am
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Sep 9th, 2026 11:13 am
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Sep 9th, 2026 5:00 am
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - Aug 31st, 2026 5:00 am
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls - Aug 26th, 2026 7:41 am
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - Aug 20th, 2026 8:40 am
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Aug 3rd, 2026 5:00 am
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Jun 9th, 2026 12:00 am
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Jun 8th, 2026 5:05 am
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Jun 8th, 2026 5:00 am
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences - Jun 1st, 2026 5:00 am
Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move - May 4th, 2026 1:09 am